Drug Type Mesenchymal stem cell therapy |
Synonyms ATCell |
Target- |
Mechanism Stem cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 1 | - | 01 Aug 2023 | |
Post Acute COVID 19 Syndrome | Phase 1 | - | 30 Dec 2022 | |
Post-Concussion Syndrome | Phase 1 | US | 01 Feb 2021 | |
Multiple Sclerosis | Phase 1 | KY | 01 Nov 2014 | |
Muscular Dystrophy, Duchenne | Preclinical | US | 02 Apr 2020 |